Page 93 - 73_03

MARIO A. GARCÍA Y COLS. AN. R. ACAD. NAC. FARM.

(10) SAGHATELIAN, A.; JESSANI, N.; JOSEPH, A.; HUMPHREY, M. and CRAVATT, B. F. (2004):
(11) Activity-based probes for the proteomic profiling of metalloproteases. Proc.
(12) Natl. Acad. Sci. U. S. A. 101: 10000-10005.
(13) RAO, B. G. (2005): Recent developments in the design of specific Matrix
(14) Metalloproteinase inhibitors aided by structural and computational studies.
(15) Curr. Pharm. Des. 11: 295-322.
WYNN, R. L. (1999): Latest FDA approvals for dentistry. Gen. Dent. 47: 19-22.
(16) BROWN, S.; BERNARDO, M. M.; LI, Z. H.; KOTRA, L. P.; TANAKA, Y.; FRIDMAN, R.
and MOBASHERY, S. (2000): Potent and selective mechanism-based inhibition
(17) of gelatinases. J. Am. Chem. Soc. 122: 6799-6800.
(18) BROWNER, M. F.; SMITH, W. W. and CASTELHANO, A. L. (1995): Matrilysin-
(19) inhibitor complexes: common themes among metalloproteases. Biochemistry
(20) (Mosc). 34: 6602-6610.
(21) SCOZZAFAVA, A. and SUPURAN, C. T. (2000): Carbonic anhydrase and matrix
metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with
(22) MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II,
and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med.
(23) Chem. 43: 3677-3687.
(24) MICHAELIDES, M. R.; DELLARIA, J. F.; GONG, J.; HOLMS, J. H.; BOUSKA, J. J.;
STACEY, J.; WADA, C. K.; HEYMAN, H. R.; CURTIN, M. L.; GUO, Y.; GOODFELLOW,
C. L.; ELMORE, I. B.; ALBERT, D. H.; MAGOC, T. J.; MARCOTTE, P. A.; MORGAN, D.
W. and DAVIDSEN, S. K. (2001): Biaryl ether retrohydroxamates as potent,
long-lived, orally bioavailable MMP inhibitors. Bioorg. Med. Chem. Lett. 11:
1553-1556.
KIKUCHI, K.; KOMATSU, K. and NAGANO, T. (2004): Zinc sensing for cellular
application. Curr. Opin. Chem. Biol. 8: 182-191.
ONARAN, M. B.; COMEAU, A. B. and SETO, C. T. (2005): Squaric acid-based
peptidic inhibitors of matrix metalloprotease-1. J. Org. Chem. 70: 10792-
10802.
HU, X.; BALAZ, S. and SHELVER, W. H. (2004): A practical approach to docking
of zinc metalloproteinase inhibitors. J. Mol. Graph. Model. 22: 293-307.
SKILES, J. W.; GONNELLA, N. C. and JENG, A. Y. (2001): The design, structure,
and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med.
Chem. 8: 425-474.
KITAMURA, K.; KANGAWA, K.; KAWAMOTO, M.; ICHIKI, Y.; NAKAMURA, S.; MATSUO, H.
and ETO, T. (1993): Adrenomedullin: a novel hypotensive peptide isolated
from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192: 553-
560.
GARCÍA, M. A.; MARTÍN-SANTAMARÍA, S.; CACHO, M.; DE LA LLAVE, F. M.; JULIAN,
M.; MARTÍNEZ, A.; DE PASCUAL-TERESA, B. and RAMOS, A. (2005): Synthesis,
biological evaluation, and three-dimensional quantitative structure-activity
relationship study of small-molecule positive modulators of adrenomedullin.
J. Med. Chem. 48: 4068-4075.
SYBYL, version 7.2.; Tripos.: St. Louis, Missouri, 1999.
MOHAMADI, F.; RICHARDS, N. G. J.; GUIDA, W. C.; LISKAMP, R.; LIPTON, M.;
CAUFIELD, C.; CHANG, G.; HENDRICKSON, T. and STILL, W. C. (1990): MacroModel

722